Becton Dickinson Retained Earnings (Accumulated Deficit) 2010-2024 | BDX
Becton Dickinson retained earnings (accumulated deficit) from 2010 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
- Becton Dickinson retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $16.015B, a 2.06% increase year-over-year.
- Becton Dickinson retained earnings (accumulated deficit) for 2023 were $15.535B, a 2.49% increase from 2022.
- Becton Dickinson retained earnings (accumulated deficit) for 2022 were $15.157B, a 9.63% increase from 2021.
- Becton Dickinson retained earnings (accumulated deficit) for 2021 were $13.826B, a 8.09% increase from 2020.
Becton Dickinson Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$15,535 |
| 2022 |
$15,157 |
| 2021 |
$13,826 |
| 2020 |
$12,791 |
| 2019 |
$12,913 |
| 2018 |
$12,596 |
| 2017 |
$13,111 |
| 2016 |
$12,727 |
| 2015 |
$12,314 |
| 2014 |
$12,105 |
| 2013 |
$11,342 |
| 2012 |
$10,435 |
| 2011 |
$9,634 |
| 2010 |
$8,724 |
| 2009 |
$7,753 |
Becton Dickinson Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$16,015 |
| 2024-03-31 |
$15,802 |
| 2023-12-31 |
$15,540 |
| 2023-09-30 |
$15,535 |
| 2023-06-30 |
$15,691 |
| 2023-03-31 |
$15,563 |
| 2022-12-31 |
$15,384 |
| 2022-09-30 |
$15,157 |
| 2022-06-30 |
$15,088 |
| 2022-03-31 |
$14,416 |
| 2021-12-31 |
$14,233 |
| 2021-09-30 |
$13,826 |
| 2021-06-30 |
$13,821 |
| 2021-03-31 |
$13,557 |
| 2020-12-31 |
$13,522 |
| 2020-09-30 |
$12,791 |
| 2020-06-30 |
$12,916 |
| 2020-03-31 |
$12,868 |
| 2019-12-31 |
$12,938 |
| 2019-09-30 |
$12,913 |
| 2019-06-30 |
$12,997 |
| 2019-03-31 |
$12,792 |
| 2018-12-31 |
$13,018 |
| 2018-09-30 |
$12,596 |
| 2018-06-30 |
$12,971 |
| 2018-03-31 |
$12,616 |
| 2017-12-31 |
$12,765 |
| 2017-09-30 |
$13,111 |
| 2017-06-30 |
$12,989 |
| 2017-03-31 |
$13,321 |
| 2016-12-31 |
$13,133 |
| 2016-09-30 |
$12,727 |
| 2016-06-30 |
$12,850 |
| 2016-03-31 |
$12,600 |
| 2015-12-31 |
$12,402 |
| 2015-09-30 |
$12,314 |
| 2015-06-30 |
$12,260 |
| 2015-03-31 |
$12,324 |
| 2014-12-31 |
$12,224 |
| 2014-09-30 |
$12,105 |
| 2014-06-30 |
$11,909 |
| 2014-03-31 |
$11,689 |
| 2013-12-31 |
$11,507 |
| 2013-09-30 |
$11,342 |
| 2013-06-30 |
$11,348 |
| 2013-03-31 |
$11,143 |
| 2012-12-31 |
$10,964 |
| 2012-09-30 |
$10,435 |
| 2012-06-30 |
$10,234 |
| 2012-03-31 |
$9,999 |
| 2011-12-31 |
$9,800 |
| 2011-09-30 |
$9,634 |
| 2011-06-30 |
$9,422 |
| 2011-03-31 |
$9,169 |
| 2010-12-31 |
$8,947 |
| 2010-09-30 |
$8,724 |
| 2010-06-30 |
$8,413 |
| 2010-03-31 |
$8,192 |
| 2009-12-31 |
$7,979 |
| 2009-09-30 |
$7,753 |
| 2009-06-30 |
$7,515 |
| 2009-03-31 |
$7,253 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical & Dental Supplies |
$64.352B |
$20.178B |
|
Becton, Dickinson and Company, is a medical technology company engaged principally in the development, manufacture and sale of medical devices, instrument systems and reagents. BD's operations consisted of three business segments: BD Medical, BD Diagnostics and BD Biosciences. The company's organizational structure was realigned to form two principal business segments: BD Medical, BD Life Sciences and BD Interventional. BD Medical: BD Medical's major product lines include needles, syringes and intravenous catheters for medication delivery and generic prefilled injectables. BD Life Sciences - BD Diagnostics provides products for the safe collection and transport of diagnostics specimens to detect a broad range of infectious diseases, healthcare-associated infections and cancer. BD Biosciences produces research and clinical tools that facilitate the study of cells to gain a better understanding of normal and disease processes. With the acquisition of C.R. Bard, BD added a new segment - BD Interventional.
|
